| ACE-I | Angiotensin-converting enzyme inhibitor |
| AGEs | Advanced glycation end products |
| AKI | Acute kidney injury |
| ARB | Angiotensin II receptor blocker |
| CKD | Chronic kidney disease |
| CRP | C-reactive protein |
| CTGF | Connective tissue growth factor |
| DKD | Diabetic kidney disease |
| ECM | Extracellular matrix |
| eGFR | Estimated glomerular filtration rate |
| GLP-1 Ras | Glucagon-like peptide-1 receptor agonists |
| JAK–STAT | Janus kinase–signal transducer and activator of transcription pathway |
| KIM-1 | Kidney injury molecule-1 |
| MCP-1 | Monocyte chemoattractant protein-1 |
| MRA | Mineralocorticoid receptor antagonist |
| NF-κB | Nuclear factor kappa-light-chain-enhancer of activated B cells |
| NGAL | Neutrophil gelatinase-associated lipocalin |
| nsMRA | Non-steroidal mineralocorticoid receptor antagonist |
| RAAS | Renin–angiotensin–aldosterone system |
| SGK1 | Serum/glucocorticoid-regulated kinase 1 |
| SGLT2 | Sodium–glucose cotransporter 2 |
| TGF-β | Transforming growth factor beta |
| TNF-α | Tumor necrosis factor-alpha |
| Wnt/β-catenin | Wingless-related integration site/beta-catenin signaling pathway |